Flumatinib manufacturers
- Flumatinib
-
- $30.00
-
2026-07-27
- CAS:895519-90-1
- Purity: 99.52%
- Supply Ability: 10g
|
| | Flumatinib Basic information |
| Product Name: | Flumatinib | | Synonyms: | BenzaMide, 4-[(4-Methyl-1-piperazinyl)Methyl]-N-[6-Methyl-5-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]-3-pyridinyl]-3-(trifluoroMethyl)-;4-[(4-Methyl-1-piperazinyl)methyl]-N-[6-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-3-pyridinyl]-3-(trifluoromethyl)benzamide;FLUMATINIB (HHGV678);HHGV678;FluMatinib;N-(6-Methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide;Flumatinib, 10 mM in DMSO;HHGV-678,Inhibitor,Flumatinib,Bcr-Abl,inhibit,Platelet-derived growth factor receptor,PDGFR,CD117,SCFR,HHGV 678,c-Kit | | CAS: | 895519-90-1 | | MF: | C29H29F3N8O | | MW: | 562.59 | | EINECS: | | | Product Categories: | API | | Mol File: | 895519-90-1.mol |  |
| | Flumatinib Chemical Properties |
| density | 1.340±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:100.0(Max Conc. mg/mL);177.75(Max Conc. mM) | | form | A solid | | pka | 11.84±0.70(Predicted) | | color | Off-white to yellow |
| | Flumatinib Usage And Synthesis |
| Uses | Flumatinib-d3 is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively[1]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Luo H, et al. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia. 2010 Oct;24(10):1807-9. DOI:10.1038/leu.2010.169
[3] Zhao J, et al. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2013 Nov 10. DOI:10.1111/cas.12320
[4] Gong A, et al. Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos. 2010 Aug;38(8):1328-40. DOI:10.1124/dmd.110.032326 |
| | Flumatinib Preparation Products And Raw materials |
|